RNA — Atrium Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2093101 ·
Last close
$11.18
Market Cap
$191.24M
52W High
$14.14
52W Low
$11.15
ADV30
209,632
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 19,635,000 | — | -17,280,000 | -16,633,000 | 292,360,000 | 267,849,000 | 58,256,000 |
| Dec 2025 | 859,000 | — | -48,035,000 | -48,069,000 | 278,353,000 | 270,000,000 | 71,066,000 |
| Sep 2025 | — | — | — | — | 277,544,000 | 270,000,000 | 64,691,000 |
| Mar 2025 | 1,573,000 | — | -7,452,000 | -7,449,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,761,000
Investing CF
$-3,195,000
Financing CF
$341,220,000
CapEx
$-3,195,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$12,128,000
Inventory
—
Receivables
$15,000,000
ST Investments
—
EBIT TTM
$-117,016,000
Pretax Income TTM
$-116,362,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,680,000
EBITDA
$-59,038,000
Free Cash Flow
—
Enterprise Value
$-69,138,328
Total Cash
$267,848,992
Total Debt
$2,680,000
Shares Out
17,105,643
Trailing EPS
$-5.02
Book Value
$13.69
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 18,618,000 | -76,814,000 | -76,684,000 | 278,353,000 | 71,066,000 | — | -41,129,000 |
| Dec 2024 | 10,897,000 | -13,218,000 | -25,122,000 | 7,186,000 | 68,294,000 | — | -22,553,000 |
| Dec 2023 | 9,764,000 | -6,386,000 | -6,385,000 | 10,293,000 | 80,912,000 | — | 56,390,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | $190.55M | $4.09 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $194.44M | $3.86 | — |
| GLSI | Greenwich LifeSciences, Inc. | $187.88M | $12.80 | — |
| MSLE | Satellos Bioscience Inc. | $195.81M | $9.40 | — |
| NBP | NovaBridge Biosciences | $186.19M | $1.61 | — |
News headlines (Yahoo Finance, 1h cache)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-20 21:58 · Yahoo
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
2026-05-28 10:24 · Yahoo
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-21 02:46 · Yahoo
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
2026-07-14 10:30 · Yahoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results
2026-05-14 20:40 · Yahoo
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
2026-04-23 12:00 · Yahoo
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
2026-03-19 17:04 · Yahoo
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
2026-03-19 08:00 · Yahoo
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
2026-03-17 12:09 · Yahoo
Sector Update: Health Care Stocks Advance Late Afternoon
2026-03-16 19:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.